Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antago

Details Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antago Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antago

1996-04-25

1997-11-11

Datlow, Philip I.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

540542, 540548, A61K 3155, C07D49804, C07D51304

Patent

active

056864450

ABSTRACT:
Tricyclic compounds of the general Formula I: ##STR1## as defined herein which exhibit antagonist activity at V.sub.1 and/or V.sub.2 receptors and exhibit in vivo vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and processes for preparing such compounds.

REFERENCES:
Albright, Chemical Abstract 123:313792y (1995) for Canadian Patent 2,128,955 (Jan. 30, 1995).
International Union of Pure and Applied Chemistry (IUPAC), vol. 82,1960, p. 5566.
Drug Evaluations, 6th Ed., 1986, Amer. Medical Assn., pp. 160-162.
Cecil Textbook of Medicine, 19th Ed., 1992, Wynoaarden, M.D., Editor, pp. 2075-2079.
Yamamura, et al., Science, 252, pp. 572-574, (1991).
Yamamura, et al., Br. J. Pharmacol., 105, pp. 787-791 (1992).

Affiliated with

Also associated with

Rating

Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antago does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antago, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridobenzoxazepine and pyridobenzothiazepine vasopressin antago will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1229325